Lyell Immunopharma - LYEL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.33
  • Forecasted Upside: 124.26%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.27
▼ -0.02 (-0.61%)

This chart shows the closing price for LYEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lyell Immunopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LYEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LYEL

Analyst Price Target is $7.33
▲ +124.26% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lyell Immunopharma in the last 3 months. The average price target is $7.33, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 124.26% upside from the last price of $3.27.

This chart shows the closing price for LYEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Lyell Immunopharma. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyLower TargetEqual Weight$7.00 ➝ $4.00Low
11/14/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $7.00Low
11/11/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$13.00 ➝ $7.00Low
11/9/2022HC WainwrightLower Target$12.00 ➝ $11.00Low
10/17/2022HC WainwrightInitiated CoverageBuy$12.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$21.00 ➝ $12.00Low
3/31/2022The Goldman Sachs GroupLower TargetBuy$31.00 ➝ $21.00High
1/6/2022Morgan StanleyLower TargetOverweight$25.00 ➝ $20.00Low
7/12/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00Medium
7/12/2021Morgan StanleyInitiated CoverageOverweight$25.00Low
7/12/2021Bank of AmericaInitiated CoverageBuy$25.00Low
7/12/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.64 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/8/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Lyell Immunopharma logo
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.27
Low: $3.14
High: $3.32

50 Day Range

MA: $3.33
Low: $2.78
High: $4.21

52 Week Range

Now: $3.27
Low: $2.74
High: $8.74

Volume

639,779 shs

Average Volume

960,811 shs

Market Capitalization

$815.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lyell Immunopharma?

The following Wall Street research analysts have issued stock ratings on Lyell Immunopharma in the last year: HC Wainwright, Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for LYEL.

What is the current price target for Lyell Immunopharma?

3 Wall Street analysts have set twelve-month price targets for Lyell Immunopharma in the last year. Their average twelve-month price target is $7.33, suggesting a possible upside of 124.3%. HC Wainwright has the highest price target set, predicting LYEL will reach $11.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $4.00 for Lyell Immunopharma in the next year.
View the latest price targets for LYEL.

What is the current consensus analyst rating for Lyell Immunopharma?

Lyell Immunopharma currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LYEL, but not buy more shares or sell existing shares.
View the latest ratings for LYEL.

What other companies compete with Lyell Immunopharma?

How do I contact Lyell Immunopharma's investor relations team?

The company's listed phone number is 650-695-0677 and its investor relations email address is [email protected] The official website for Lyell Immunopharma is www.lyell.com. Learn More about contacing Lyell Immunopharma investor relations.